Nordea Investment Boosts Stake in Neurocrine Biosciences

Institutional investor increases holdings in biotech firm by over 80%

Mar. 28, 2026 at 9:00am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB, a major institutional investor, has significantly increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 81.3% during the fourth quarter, according to a recent SEC filing. The firm now owns 27,202 shares of the biopharmaceutical company's stock, valued at $3.8 million.

Why it matters

This move by Nordea Investment highlights the continued investor interest and confidence in Neurocrine Biosciences, a leading developer of treatments for neurological and endocrine disorders. As the company works to expand its portfolio and commercialize new therapies, institutional backing from major firms like Nordea can provide important financial and strategic support.

The details

According to the 13F filing, Nordea Investment Management acquired an additional 12,195 shares of Neurocrine Biosciences during the fourth quarter of 2025, bringing its total position to 27,202 shares. This represents an 81.3% increase in the firm's holdings of the biotech company's stock. Nordea's investment in Neurocrine Biosciences is now valued at approximately $3.8 million as of the most recent SEC reporting period.

  • Nordea Investment Management filed its 13F report for the fourth quarter of 2025 on March 28, 2026.
  • The firm increased its Neurocrine Biosciences stake during the fourth quarter of 2025.

The players

Nordea Investment Management AB

A major institutional investor and asset management firm based in the Nordic countries.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological and endocrine disorders, including its lead marketed product Ingrezza for tardive dyskinesia.

Got photos? Submit your photos here. ›

The takeaway

Neurocrine Biosciences continues to attract strong institutional backing as it advances its portfolio of innovative neurological and endocrine disorder treatments. This latest investment by Nordea Investment Management underscores the biotech firm's position as a leader in its field and its promising outlook for future growth and success.